These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2822649)

  • 21. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of the new cyclic lipopeptide LY146032 against Corynebacterium species.
    Spitzer PG; Eliopoulos GM; Karchmer AW; Moellering RC
    Eur J Clin Microbiol; 1987 Apr; 6(2):183-5. PubMed ID: 3036499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S; Warner M; Johnson AP; Livermore DM
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro susceptibility of staphylococci and streptococci and influence of agar media on minimum inhibitory concentration.
    Washington JA; Hermans PE; Martin WJ
    Mayo Clin Proc; 1970 Jul; 45(7):527-35. PubMed ID: 5434106
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative in vitro activity of the new peptolide antibiotic LY146032 against staphylococci.
    Peters G; Schumacher-Perdreau F; Pulverer G
    Eur J Clin Microbiol; 1987 Dec; 6(6):685. PubMed ID: 2831047
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci.
    Bryant RE; Mazza JA; Gardner EM
    Eur J Clin Microbiol; 1987 Apr; 6(2):186-8. PubMed ID: 3036500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of teichomycin against isolates of gram-positive bacteria.
    Fietta A; Bersani C; Mangiarotti P; Gialdroni Grassi G
    Chemotherapy; 1983; 29(4):275-82. PubMed ID: 6223793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro evaluation of the new paulomycin antibiotic paldimycin.
    Eliopoulos GM; Reiszner E; Moellering RC
    Eur J Clin Microbiol; 1987 Jun; 6(3):306-8. PubMed ID: 3622497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
    Saito H; Rolston KV; Ho DH; LeBlanc B; Bodey GP
    J Antimicrob Chemother; 1987 Oct; 20(4):497-503. PubMed ID: 2824425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
    Jones RN; Barry AL
    Antimicrob Agents Chemother; 1987 Apr; 31(4):625-9. PubMed ID: 3038001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.
    Flandrois JP; Fardel G; Carret G
    Antimicrob Agents Chemother; 1988 Apr; 32(4):454-7. PubMed ID: 2837137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbiological properties of teicoplanin.
    Greenwood D
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():1-13. PubMed ID: 2965119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P; Grenier P; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.
    Debbia E; Pesce A; Schito GC
    Antimicrob Agents Chemother; 1988 Feb; 32(2):279-81. PubMed ID: 2834999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.
    Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Mar; 37(3):605-9. PubMed ID: 8384822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro effect of vancomycin and daptomycin on biofilm formation of coagulase-negative staphylococci strains].
    Öcal DN; Dolapçı İ; Gençtürk Z; Tekeli A
    Mikrobiyol Bul; 2017 Jul; 51(3):220-235. PubMed ID: 28929959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of calcium on in vitro activity of LY146032 against Clostridium difficile.
    Faruki H; Niles AC; Heeren RL; Murray PR
    Antimicrob Agents Chemother; 1987 Mar; 31(3):461-2. PubMed ID: 3034146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.